ANTI-BCMA CAR T CELL COMPOSITIONS
The invention provides improved anti-BCMA CAR T cell compositions for adoptive T cell therapy for relapsed/refractory multiple myeloma.
1 . A composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells, wherein the therapeutically effective amount is greater than 45.0×10 7 to less than 80×10 7 anti-BCMA CAR T cells, wherein the anti-BCMA CAR comprises the amino acids 22-493 of the amino acid sequence set forth in SEQ ID NO: 9, and wherein the composition is formulated for intravenous administration in a single dose.
2 . The composition of claim 1 , comprising 50:50 PlasmaLyte A to CryoStor CS10.
3 .- 10 . (canceled)
11 . The composition of claim 1 , wherein the anti-BCMA CAR comprises the amino acid sequence of SEQ ID NO: 9.
12 . The composition of claim 1 , wherein the anti-BCMA CAR is encoded by the nucleotide sequence set forth in SEQ ID NO: 10.
13 . The composition of claim 1 , wherein the anti-BCMA CAR T cells were produced by transduction with a lentiviral vector encoding the anti-BCMA CAR.
14 . The composition of claim 13 , wherein the lentiviral vector is a human immunodeficiency virus vector.
15 . The composition of claim 1 , wherein the T cells comprise CD8+ T cells.
16 . A composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells, wherein the therapeutically effective amount is 45.0×10 7 ±20% anti-human BCMA CAR T cells, wherein the anti-BCMA CAR comprises amino acids 22-493 of the amino acid sequence set forth in SEQ ID NO: 9, and wherein the composition is formulated for intravenous administration in a single dose.
17 . The composition of claim 16 , comprising 50:50 PlasmaLyte A to CryoStor CS10.
18 . The composition of claim 16 , wherein the anti-BCMA CAR comprises the amino acid sequence of SEQ ID NO: 9.
19 . The composition of claim 16 , wherein the anti-BCMA CAR is encoded by the nucleotide sequence set forth in SEQ ID NO: 10.
20 . The composition of claim 16 , wherein the anti-BCMA CAR T cells were produced by transduction with a lentiviral vector encoding the anti-BCMA CAR.
21 . The composition of claim 20 , wherein the lentiviral vector is a human immunodeficiency virus vector.
22 . The composition of claim 16 , wherein the T cells comprise CD8+ T cells.